Search

Your search keyword '"Cameron, Silke"' showing total 303 results
Start Over Author "Cameron, Silke"
303 results on '"Cameron, Silke"'

5. Traditional clinical symptoms and signs: Kampo pattern diagnosis in modern gastrointestinal disease.

Author

Zedler, Paul, Büntzel, Judith, Kuchta, Kenny, Denichiro Yamaoka, Nanoha Sato, Kenji Watanabe, and Cameron, Silke

Subjects
INFLAMMATORY bowel diseases, SYMPTOMS, IRRITABLE colon, JAPANESE herbal medicine, ABDOMINAL diseases
Abstract

Introduction: In traditional Japanese Kampo medicine, a profound anamnesis is completed by clinical examination. The resulting clinical image forms the basis of the patient’s diagnosis pattern, including the recent mental, physical, and social contexts. Kampo questionnaires support pattern diagnosis and bridge traditional and Western medicine diagnoses. Aims of the study: Traditional Kampo therapy is tailored to a specific body constitution, while Western medicine treatment is tailored to a specific disease. The aims of this study were to analyze whether traditional Kampo diagnosis is applicable to German patients and whether specific symptom patterns are characteristic for defined diseases. Material and methods: This study validates for the first time a Kampo questionnaire adapted for German patients. The analysis focuses on patients with gastrointestinal diseases, the main field for Kampo medicines. Results: In total, we prospectively included 251 participants; of those, 58 were cancer patients (23.1%), 35 had Crohn’s disease (13.9%), 18 had ulcerative colitis (7.2%), 17 had irritable bowel syndrome (6.8%), and 103 had other abdominal diseases (41%), as well as 20 German controls (8%). The patient population consisted of 144 female (57.4%) and 107 male (42.6%) participants. The median age was 65 years. The disease duration (average: 211 months) varied from 1 month (cancer patient) to 540 months (patient with Crohn’s disease). The scores for questions on the state of mind were significantly higher in patients with inflammatory bowel disease (IBD) as well as irritable bowel syndrome (IBS)— in comparison to the tumor and control groups. This was reflected in questions about abdominal discomfort, appetite, fecal habits, and cold sensation. Accordingly, symptoms of Qi (i.e., vital energy) deficiency were mostly observed in patients with chronic diseases such as Crohn’s disease and ulcerative colitis. Defined symptom combinations did not reflect conventional Western diagnosis. Conclusion: Our study results show that symptom patterns are independent of the underlying disease. They rather depict the individual patient within an individual time frame. Traditional Kampo questionnaires were found to be valid for the analysis of a patients’ body constitution (sho) and serve as a guide for Kampo treatment. We propose that individual pattern diagnosis should be taken into account to help treatment individualization. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis

Author

Ammer-Herrmenau, Christoph, primary, Antweiler, Kai L, additional, Asendorf, Thomas, additional, Beyer, Georg, additional, Buchholz, Soeren M, additional, Cameron, Silke, additional, Capurso, Gabriele, additional, Damm, Marko, additional, Dang, Linh, additional, Frost, Fabian, additional, Gomes, Antonio, additional, Hamm, Jacob, additional, Henker, Robert, additional, Hoffmeister, Albrecht, additional, Meinhardt, Christian, additional, Nawacki, Lukasz, additional, Nunes, Vitor, additional, Panyko, Arpad, additional, Pardo, Cesareo, additional, Phillip, Veit, additional, Pukitis, Aldis, additional, Rasch, Sebastian, additional, Riekstina, Diana, additional, Rinja, Ecaterina, additional, Ruiz-Rebollo, María Lourdes, additional, Sirtl, Simon, additional, Weingarten, Mark, additional, Sandru, Vasile, additional, Woitalla, Julia, additional, Ellenrieder, Volker, additional, and Neesse, Albrecht, additional

Published
2023
Full Text
View/download PDF

10. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

Author

Mechie, Nicolae-Catalin, Röver, Christian, Cameron, Silke, and Amanzada, Ahmad

Subjects
Quantitative Biology - Quantitative Methods, Statistics - Applications
Abstract

AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-$\alpha$ (Peg-INF-$\alpha$) based triple-therapy. METHODS: We searched PubMed, the Cochrane Library and Web of Knowledge for studies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitor based triple-therapy. Ten studies with 2707 patients were included into this meta-analysis. We used regression methods in order to investigate determinants of SVR. RESULTS: IL-28B-CC-genotype patients achieved higher SVR rates (odds 5.34, CI: 3.81-7.49) than IL-28B-non-CC-genotype patients (1.88, CI: 1.43-2.48) receiving triple-therapy. The line of therapy (treatment-na\"ive or -experienced for Peg-INF-$\alpha$) did not affect the predictive value of IL-28B (p=0.1). IL-28B-CC-genotype patients treated with protease inhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telaprevir or Vaniprevir showed odds of 1.86, 9.77, 4.51 and 0.89, respectively. The odds for CC genotype patients treated with Faldaprevir cannot be quantified, as only a single study with a 100% SVR rate was available. CONCLUSION: IL-28B-SNP predicts the outcome for chronic HCV genotype-1 patients receiving protease inhibitor-based triple-therapy. The predictive value varies between the different protease inhibitors., Comment: 21 pages, 3 figures, 1 table

Published
2014
Full Text
View/download PDF

11. Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis.

Author

Ammer-Herrmenau, Christoph, Antweiler, Kai L., Asendorf, Thomas, Beyer, Georg, Buchholz, Soeren M., Cameron, Silke, Capurso, Gabriele, Damm, Marko, Linh Dang, Frost, Fabian, Gomes, Antonio, Hamm, Jacob, Henker, Robert, Hoffmeister, Albrecht, Meinhardt, Christian, Nawacki, Lukasz, Nunes, Vitor, Panyko, Arpad, Pardo, Cesareo, and Phillip, Veit

Subjects
NECROTIZING pancreatitis, NONINVASIVE ventilation, SHOTGUN sequencing, GUT microbiome, PANCREATITIS
Published
2024
Full Text
View/download PDF

12. Pancreatitis - Microbiome As Predictor of Severity (P-MAPS): a prospective international multicentre translational study

Author

Ammer-Herrmenau, Christoph, primary, Antweiler, Kai, additional, Apadula, Laura, additional, Asendorf, Thomas, additional, Beyer, Georg, additional, Buchholz, Soeren, additional, Cameron, Silke, additional, Capurso, Gabriele, additional, Damm, Marko, additional, Frost, Fabian, additional, Gomes, Antonio, additional, Henker, Robert, additional, Hoffmeister, Albrecht, additional, Meinhardt, Christian, additional, Nawacki, Lukasz, additional, Nunes, Vitor, additional, Panyko, Arpad, additional, Pardo, Cesareo, additional, Phillip, Veit, additional, Pukitis, Aldis, additional, Rasch, Sebastian, additional, Riekstina, Diana, additional, Rinja, Ecaterina, additional, Lourdes, Ruiz Rebollo, additional, Sirtl, Simon, additional, Weingarten, Mark, additional, Vasile, Sandru, additional, Woitalla, Julia, additional, Ellenrieder, Volker, additional, and Neesse, Albrecht, additional

Published
2023
Full Text
View/download PDF

13. Supplementary Figure S2 from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Author

Joensuu, Heikki, primary, Wardelmann, Eva, primary, Eriksson, Mikael, primary, Reichardt, Annette, primary, Hall, Kirsten Sundby, primary, Schütte, Jochen, primary, Cameron, Silke, primary, Hohenberger, Peter, primary, Sihto, Harri, primary, Jost, Philipp J., primary, Lindner, Lars H., primary, Bauer, Sebastian, primary, Nilsson, Bengt, primary, Kallio, Raija, primary, Pesonen, Tommi, primary, and Reichardt, Peter, primary

Published
2023
Full Text
View/download PDF

14. Study Protocol from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Author

Joensuu, Heikki, primary, Wardelmann, Eva, primary, Eriksson, Mikael, primary, Reichardt, Annette, primary, Hall, Kirsten Sundby, primary, Schütte, Jochen, primary, Cameron, Silke, primary, Hohenberger, Peter, primary, Sihto, Harri, primary, Jost, Philipp J., primary, Lindner, Lars H., primary, Bauer, Sebastian, primary, Nilsson, Bengt, primary, Kallio, Raija, primary, Pesonen, Tommi, primary, and Reichardt, Peter, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table S1 from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Author

Joensuu, Heikki, primary, Wardelmann, Eva, primary, Eriksson, Mikael, primary, Reichardt, Annette, primary, Hall, Kirsten Sundby, primary, Schütte, Jochen, primary, Cameron, Silke, primary, Hohenberger, Peter, primary, Sihto, Harri, primary, Jost, Philipp J., primary, Lindner, Lars H., primary, Bauer, Sebastian, primary, Nilsson, Bengt, primary, Kallio, Raija, primary, Pesonen, Tommi, primary, and Reichardt, Peter, primary

Published
2023
Full Text
View/download PDF

16. Data from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Author

Joensuu, Heikki, primary, Wardelmann, Eva, primary, Eriksson, Mikael, primary, Reichardt, Annette, primary, Hall, Kirsten Sundby, primary, Schütte, Jochen, primary, Cameron, Silke, primary, Hohenberger, Peter, primary, Sihto, Harri, primary, Jost, Philipp J., primary, Lindner, Lars H., primary, Bauer, Sebastian, primary, Nilsson, Bengt, primary, Kallio, Raija, primary, Pesonen, Tommi, primary, and Reichardt, Peter, primary

Published
2023
Full Text
View/download PDF

19. KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Author

Joensuu, Heikki, primary, Wardelmann, Eva, additional, Eriksson, Mikael, additional, Reichardt, Annette, additional, Hall, Kirsten Sundby, additional, Schütte, Jochen, additional, Cameron, Silke, additional, Hohenberger, Peter, additional, Sihto, Harri, additional, Jost, Philipp J., additional, Lindner, Lars H., additional, Bauer, Sebastian, additional, Nilsson, Bengt, additional, Kallio, Raija, additional, Pesonen, Tommi, additional, and Reichardt, Peter, additional

Published
2023
Full Text
View/download PDF

25. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer

Author

Krebs, Niklas, primary, Klein, Lukas, additional, Wegwitz, Florian, additional, Espinet, Elisa, additional, Maurer, Hans Carlo, additional, Tu, Mengyu, additional, Penz, Frederike, additional, Küffer, Stefan, additional, Xu, Xingbo, additional, Bohnenberger, Hanibal, additional, Cameron, Silke, additional, Brunner, Marius, additional, Neesse, Albrecht, additional, Kishore, Uday, additional, Hessmann, Elisabeth, additional, Trumpp, Andreas, additional, Ströbel, Philipp, additional, Brekken, Rolf A., additional, Ellenrieder, Volker, additional, and Singh, Shiv K., additional

Published
2022
Full Text
View/download PDF

34. Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factor

Author

Haller, Florian, Zhang, Jitao David, Moskalev, Evgeny A., Braun, Alexander, Otto, Claudia, Geddert, Helene, Riazalhosseini, Yasser, Ward, Aoife, Balwierz, Aleksandra, Schaefer, Inga-Marie, Cameron, Silke, Ghadimi, Michael B., Agaimy, Abbas, Fletcher, Jonathan A., Hoheisel, Jörg, Hartmann, Arndt, Werner, Martin, Wiemann, Stefan, and Sahin, Özgür

Published
2015
Full Text
View/download PDF

42. Phytotherapy for Cachexia: Where Do We Stand?

Author

Kuchta, Kenny and Cameron, Silke

Subjects
phytotherapy, cachexia, Kampo (traditional Japanese herbal medicine), Hozai, adaptogen, mechanistictarget of rapamycin, melatonin, interleukin, Pharmacology, lcsh:RM1-950, Review, lcsh:Therapeutics. Pharmacology, mechanistic target of rapamycin
Abstract

Background: In contrast to Western medicine which currently offers no approved pharmacotherapy options for cachexia, in Japan multi-component extracts of medicinal plants are used with coverage by the national health insurance. This so called “Kampo” medicine is an example of the modern concept of multi-component/multi-target therapy. For the three traditional preparations Hochuekkito (補中益気湯), Juzentaihoto (十全大補湯), and Rikkunshito (六君子湯), a multitude of clinical research data relating to cachexia has been published. These preparations are also referred to as “Hozai” (補剤). A similar concept is found in Russian herbal medicine, where the term “Adaptogen” was coined for pharmacologically active substances which enhance adaptive stress repose. Methods: Scientific literature—including original Japanese articles—was reviewed regarding the effects of these herbal preparations on cachexia. Cachexia is a complex set of symptoms including muscle atrophy with loss of weight, fatigue, and weakness. Results: In a 1985 study by Kuroda et al., Hochuekkito showed efficacy in involuntary weight loss and fatigue in 63% of 162 patients with genitourinary cancer. For cancer-related fatigue, a significant improvement was reported within 2 weeks by Jeong et al. in 2010. In patients with chronic fatigue syndrome, Hochuekkito showed an overall improvement with 8–12 weeks of therapy in a 1997 study by Kuratsune et al. In a 2005 randomized placebo-controlled trial by Satoh et al. on 13 geriatric Q1 patients in a 16-week treatment protocol, Hochuekkito showed significant improvement of general health, physical functioning and the Profile of Mood States (POMS). In 71 geriatric COPD patients in a 2009 placebo-controlled randomized study, Tatsumi et al. found a significant body weight increase and a CRP, TNF-α, IL-6 decrease over 6 months of therapy. For Juzentaihoto in 48 hepatocellular carcinoma patients, Tsuchiya et al. 2008 documented a significantly longer recurrence-free survival (49 vs. 24 months) as compared to the control group (p=0.023). For the much simpler Rikkunshito prescription, a 2011 retrospective study by Fujitsuka et al. on 39 Stage III/IV pancreatic cancer patients treated with Gemcitabine (n=33) or Gemcitabine/Rikkunshito (n=6) showed a significantly prolonged median survival with 224 vs. 378.5 days (p < 0.05). In a 2011 open-label clinical study by Utumi et al. on geriatric cachexia in 6 dementia patients, treatment with Rikkunshito for 4 weeks resulted in a significant body weight increase. In all the above studies, the standardized dosage of 3x2.5 g/d extract granules for most Japanese health insurance-covered Kampo extract-preparations was applied. Conclusion: As there is currently no accepted pharmacotherapy option for cachexia available in the West, a transfer of these East Asian gold standard prescriptions into the European market would be desirable. We were further able to demonstrate that the mTOR, interleucin, and melatonin pathways are modified by herbal compounds which thus counteract cachexia. More research in this field is urgently needed in order to provide new, effective treatments for cachexia patients. Open-Access-Publikationsfonds 2020 peerReviewed

Published
2020

46. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

Author

Joensuu, Heikki, primary, Eriksson, Mikael, additional, Sundby Hall, Kirsten, additional, Reichardt, Annette, additional, Hermes, Barbara, additional, Schütte, Jochen, additional, Cameron, Silke, additional, Hohenberger, Peter, additional, Jost, Philipp J., additional, Al-Batran, Salah-Eddin, additional, Lindner, Lars H., additional, Bauer, Sebastian, additional, Wardelmann, Eva, additional, Nilsson, Bengt, additional, Kallio, Raija, additional, Jaakkola, Panu, additional, Junnila, Jouni, additional, Alvegård, Thor, additional, and Reichardt, Peter, additional

Published
2020
Full Text
View/download PDF

47. Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.

Author

Joensuu, Heikki, primary, Eriksson, Mikael, additional, Sundby Hall, Kirsten, additional, Reichardt, Annette, additional, Hermes, Barbara, additional, Schuette, Jochen, additional, Cameron, Silke, additional, Hohenberger, Peter, additional, Jost, Philipp, additional, Al-Batran, Salah-Eddin, additional, Lindner, Lars H, additional, Bauer, Sebastian, additional, Wardelmann, Eva, additional, Nilsson, Bengt E., additional, Kallio, Raija S., additional, Jaakkola, Panu, additional, Junnila, Jouni, additional, Alvegard, Thor, additional, and Reichardt, Peter, additional

Published
2020
Full Text
View/download PDF

49. Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer.

Author

Golas, Mariola Monika, Gunawan, Bastian, Cakir, Meliha, Cameron, Silke, Enders, Christina, Liersch, Torsten, Füzesi, Laszlo, and Sander, Bjoern

Subjects
COLORECTAL cancer, HEREDITARY nonpolyposis colorectal cancer, LYMPHATIC metastasis
Abstract

Aim: Colorectal carcinomas (CRCs) progress through heterogeneous pathways. The aim of this study was to analyse whether or not the cytogenetic evolution of CRC is linked to tumour site, level of chromosomal imbalance and metastasis. Method: A set of therapy‐naïve pT3 CRCs comprising 26 proximal and 49 distal pT3 CRCs was studied by combining immunohistochemistry of mismatch repair (MMR) proteins, microsatellite analyses and molecular karyotyping as well as clinical parameters. Results: A MMR deficient/microsatellite‐unstable (dMMR/MSI‐H) status was associated with location of the primary tumour proximal to the splenic flexure, and dMMR/MSI‐H tumours presented with significantly lower levels of chromosomal imbalances compared with MMR proficient/microsatellite‐stable (pMMR/MSS) tumours. Oncogenetic tree modelling suggested two evolutionary clusters characterized by dMMR/MSI‐H and chromosomal instability (CIN), respectively, for both proximal and distal CRCs. In CIN cases, +13q, −18q and +20q were predicted as preferentially early events, and −1p, −4 ‐and −5q as late events. Separate oncogenetic tree models of proximal and distal cases indicated similar early events independent of tumour site. However, in cases with high CIN defined by more than 10 copy number aberrations, loss of 17p occurred earlier in cytogenetic evolution than in cases showing low to moderate CIN. Differences in the oncogenetic trees were observed for CRCs with lymph node and distant metastasis. Loss of 8p was modelled as an early event in node‐positive CRC, while +7p and +8q comprised early events in CRC with distant metastasis. Conclusion: CRCs characterized by CIN follow multiple, interconnected genetic pathways in line with the basic 'Vogelgram' concept proposed for the progression of CRC that places the accumulation of genetic changes at centre of tumour evolution. However, the timing of specific genetic events may favour metastatic potential. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors

Author

Matyakhina, Ludmila, Bei, Thalia A., McWhinney, Sarah R., Pasini, Barbara, Cameron, Silke, Gunawan, Bastian, Stergiopoulos, Sotirios G., Boikos, Sosipatros, Muchow, Michael, Dutra, Amalia, Pak, Evgenia, Campo, Elias, Cid, Maria C., Gomez, Fulgencio, Gaillard, Rolf C., Assie, Guillaume, Füzesi, Laszlo, Baysal, Bora E., Eng, Charis, Carney, J Aidan, and Stratakis, Constantine A.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results